carbamates has been researched along with Kidney Diseases in 21 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the safety and efficacy of direct-acting antivirals (DAAs) including sofosbuvir, ledipasvir and daclatasvir in patients with hepatitis C viraemia who were on maintenance haemodialysis." | 7.88 | Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. ( Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018) |
| "The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection." | 5.24 | Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. ( Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H, 2017) |
| "This study evaluates the safety and efficacy of direct-acting antivirals (DAAs) including sofosbuvir, ledipasvir and daclatasvir in patients with hepatitis C viraemia who were on maintenance haemodialysis." | 3.88 | Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. ( Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018) |
| "The objective of this study was to describe a population pharmacokinetic analysis of gabapentin enacarbil in patients with varying degrees of renal function, using data from an open-label study of gabapentin enacarbil in patients with renal impairment (XenoPort, Inc." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| "Repaglinide was safe and well tolerated in subjects with varying degrees of renal impairment." | 2.69 | Pharmacokinetics of repaglinide in subjects with renal impairment. ( Andersen, MP; Hatorp, V; Huang, WC; Marbury, TC; Nielsen, KK; Ruckle, JL; Strange, P, 2000) |
| "Cinacalcet hydrochloride was found to be cost effective only for those who cannot undergo parathyroidectomy." | 2.48 | [Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD]. ( Hamano, T, 2012) |
| "Repaglinide (RG) is a prandial glucose regulator used for the treatment of type 2 diabetes." | 1.48 | Repaglinide inhibits cyclosporine A-induced renal tubular toxicity\ by affecting apoptosis and \ Bax\ and \ Bcl-2\ expression ( Li, H; Li, J; Li, Q; Xue, Y, 2018) |
| " We constructed physiologically based pharmacokinetic (PBPK) models for 3 nonrenally eliminated drugs (sildenafil, repaglinide, and telithromycin)." | 1.38 | Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ( Abernethy, DR; Arya, V; Atkinson, AJ; Berglund, EG; Grillo, JA; Huang, SM; Lesko, LJ; Pang, KS; Reynolds, KS; Song, P; Sugiyama, Y; Vieira, Mde L; Wu, TC; Zhang, L; Zhao, P; Zheng, JH, 2012) |
| "Treatment of carbendazim-treated rats with the powder of tuberous root of Withania somnifera (Ashwagandha) for 48 days resulted in complete cure of these organs." | 1.31 | Curative property of Withania somnifera Dunal root in the context of carbendazim-induced histopathological changes in the liver and kidney of rat. ( Akbarsha, MA; Faridha, A; Girija, R; Kadalmani, B; Vijendrakumar, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zalawadiya, SK | 1 |
| Lindenfeld, J | 1 |
| Shah, A | 1 |
| Wigger, M | 1 |
| Danter, M | 1 |
| Brinkley, DM | 1 |
| Menachem, J | 1 |
| Punnoose, L | 1 |
| Balsara, K | 1 |
| Brown Sacks, S | 1 |
| Ooi, H | 1 |
| Perri, R | 1 |
| Awad, J | 1 |
| Smith, S | 1 |
| Fowler, R | 1 |
| O'Dell, H | 1 |
| Darragh, C | 1 |
| Ruzevich-Scholl, S | 1 |
| Schlendorf, K | 1 |
| Akhil, MS | 1 |
| Kirushnan, B | 1 |
| Martin, M | 1 |
| Arumugam, K | 1 |
| Ganesh Prasad, NK | 1 |
| Ravichandran, R | 1 |
| Takakusagi, S | 1 |
| Sato, K | 1 |
| Suzuki, Y | 1 |
| Yamazaki, Y | 1 |
| Kosone, T | 1 |
| Kakizaki, S | 1 |
| Kusano, M | 1 |
| Takagi, H | 1 |
| Flamm, SL | 1 |
| Rumi, MG | 1 |
| Occhipinti, V | 1 |
| Li, J | 1 |
| Li, H | 1 |
| Li, Q | 1 |
| Xue, Y | 1 |
| Zeltz, C | 1 |
| Gullberg, D | 1 |
| El-Bini Dhouib, I | 1 |
| Annabi, A | 1 |
| Jrad, A | 1 |
| El-Golli, N | 1 |
| Gharbi, N | 1 |
| Lasram, MM | 1 |
| El-Fazaa, S | 1 |
| Khatri, A | 1 |
| Dutta, S | 1 |
| Marbury, TC | 2 |
| Preston, RA | 1 |
| Rodrigues, L | 1 |
| Wang, H | 1 |
| Awni, WM | 1 |
| Menon, RM | 1 |
| Lal, R | 1 |
| Sukbuntherng, J | 1 |
| Luo, W | 1 |
| Chen, D | 1 |
| Blumenthal, R | 1 |
| Ho, J | 1 |
| Cundy, KC | 1 |
| Zhao, P | 1 |
| Vieira, Mde L | 1 |
| Grillo, JA | 1 |
| Song, P | 1 |
| Wu, TC | 1 |
| Zheng, JH | 1 |
| Arya, V | 1 |
| Berglund, EG | 1 |
| Atkinson, AJ | 1 |
| Sugiyama, Y | 1 |
| Pang, KS | 1 |
| Reynolds, KS | 1 |
| Abernethy, DR | 1 |
| Zhang, L | 1 |
| Lesko, LJ | 1 |
| Huang, SM | 1 |
| Joki, N | 1 |
| Iwasaki, M | 1 |
| Hamano, T | 1 |
| Sheridan, C | 1 |
| Oimomi, M | 1 |
| Ishikawa, K | 1 |
| Kawasaki, T | 1 |
| Kubota, S | 1 |
| Yoshimura, Y | 1 |
| Baba, S | 1 |
| Frazao, JM | 1 |
| Barth, RH | 1 |
| Berlyne, GM | 1 |
| Ruckle, JL | 1 |
| Hatorp, V | 1 |
| Andersen, MP | 1 |
| Nielsen, KK | 1 |
| Huang, WC | 1 |
| Strange, P | 1 |
| Akbarsha, MA | 1 |
| Vijendrakumar, S | 1 |
| Kadalmani, B | 1 |
| Girija, R | 1 |
| Faridha, A | 1 |
| Salplachta, J | 1 |
| Strnadová, V | 1 |
| Csöllei, J | 1 |
| Kraybill, HF | 1 |
3 reviews available for carbamates and Kidney Diseases
| Article | Year |
|---|---|
Post-translational modifications of integrin ligands as pathogenic mechanisms in disease.
Topics: Amidohydrolases; Carbamates; Cell Adhesion; Diabetes Mellitus; Extracellular Matrix Proteins; Fibron | 2014 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Vascular calcification in CKD patients].
Topics: Bone Diseases, Metabolic; Calcium; Carbamates; Chelating Agents; Chronic Disease; Disease Progressio | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit An | 2012 |
3 trials available for carbamates and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Analgesics; Anticonvulsants; Biomarkers; Biotransformation; Carba | 2012 |
Pharmacokinetics of repaglinide in subjects with renal impairment.
Topics: Adult; Analysis of Variance; Area Under Curve; Carbamates; Creatinine; Female; Gas Chromatography-Ma | 2000 |
15 other studies available for carbamates and Kidney Diseases
| Article | Year |
|---|---|
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; H | 2020 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluore | 2018 |
Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.
Topics: Aged, 80 and over; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Female; Glomeru | 2018 |
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease-Author's reply.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imid | 2018 |
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imid | 2018 |
Repaglinide inhibits cyclosporine A-induced renal tubular toxicity\
by affecting apoptosis and \
Bax\
and \
Bcl-2\
expression
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carbamates; Cyclosporine; Hypoglycemic Agents; Kidne | 2018 |
Carbosulfan-induced oxidative damage following subchronic exposure and the protective effects of N-acetylcysteine in rats.
Topics: Acetylcysteine; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug | 2015 |
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
Topics: Area Under Curve; Carbamates; Chronic Disease; Computer Simulation; Drug Interactions; Humans; Ketol | 2012 |
Calamitous HCV trial casts shadow over nucleoside drugs.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; DNA-Directed RNA Polymerases; Drug | 2012 |
Plasma carbamylated protein in renal failure.
Topics: Blood Proteins; Carbamates; Cyanates; Kidney Diseases | 1983 |
Carbamylated hemoglobin in prerenal azotemia.
Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Carbamates; Creatinine; Diagnosis, Differential; Femal | 1995 |
Curative property of Withania somnifera Dunal root in the context of carbendazim-induced histopathological changes in the liver and kidney of rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Carbamates; Chemical and Drug Indu | 2000 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials a | 1998 |
[Effect of Consupren, Carvedilol and BL-443 on the composition of lactate dehydrogenase in tissues of rats with cyclosporin nephropathy].
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Carbamates; Carbazoles; Carvedilol; Cyclos | 2002 |
Significance of pesticide residues in foods in relation to total environmental stress.
Topics: Adipose Tissue; Aerosols; Air Pollution; Animals; Carbamates; Chemical Industry; Chemistry, Agricult | 1969 |